Presentazione sul tema: "Terapie antiangiogenetiche: revisione e gestione degli eventi avversi Lucia Del Mastro SS Sviluppo Terapie Innovative Modena- 18 Novembre 2011 IRCCS Azienda."— Transcript della presentazione:
Terapie antiangiogenetiche: revisione e gestione degli eventi avversi Lucia Del Mastro SS Sviluppo Terapie Innovative Modena- 18 Novembre 2011 IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro
Fatal adverse event – Death caused in all likelihhod by a drug -> major cause of fatality in USA – 0.3% in prespective studies – 4.6% of all hospital fatality
CAIRO study tested the optimal use of well- established cyctotoxic (capecitabine, irinoteca, oxaliplatin) 820 enrolled patients – 112 deaths (14%) occurring within 30 days of last administration of study drug 72 (9%) deaths caused by PD 40 (5%) deaths without PD
Relationship between cause of death and study drugs changed in 65% of patients -> underestimation by local investigators of the relation between the administration of study drugs and death
Bevacizumab and osteonecrosis of the jaw Hypothesis: because healing after mucosal trauma requires re-vascularization, the combination of Beva and a biphosphonate could affect the incidence, the time to development of ONJ and/or the response to dental therapy.
Bevacizumab and osteonecrosis of the jaw ONJ incidence Biphosphonate alone1-6% 1 Bevacizumab alone0.3-1% 2,3 Bevacizumab + biphosphonate0.9-2.4% 2 1.Hoff AO, Ann NY Acad Sci 1218: 47-54; 2011 2.Guarneri V Breast Cancer Res Treat 122: 181-188; 2010 3.McArthur HL, ASCO 2008; abstr 9588